EMPLICITI (elotuzumab) for injection
EMPLICITI is a prescription medicine used to treat multiple myeloma in combination with the medicines: REVLIMID® (lenalidomide) and dexamethasone in adults who have received one to three prior treatments for their multiple myeloma. Brand Name: EMPLICITI (elotuzumab) for injection, for intravenous use Initial U.S. Approval: 2015
Home | (elotuzumab) for injection
Submit a request to access drug used to treat, diagnose or prevent serious or life-threatening conditions.We’ll get back to you within 1 business days!
For Indian Patient inquires under NPP.
For any urgent inquiries or assistance needed, please reach out to our Support Team. Rest assured, we will respond within 24 hours, from Monday to Saturday, during the hours of 9:00 A.M to 18:00 PM.
EMPLICITI (elotuzumab) for injection
Elotuzumab is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor.
Empliciti is a medicine for treating multiple myeloma (a cancer of the bone marrow). It is used together with two other medicines (lenalidomide and dexamethasone) and is given to adults who have received at least one previous cancer treatment.
Empliciti is also used together with the medicines pomalidomide and dexamethasone to treat multiple myeloma that was previously treated with at least two other treatments but the cancer had come back. Patients’ previous treatment should have included the multiple myeloma medicines lenalidomide and a class of medicines called proteasome inhibitors (e.g. bortezomib, carfilzomib and ixazomib).
Empliciti contains the active substance elotuzumab.
A drug used with dexamethasone and either lenalidomide or pomalidomide to treat adults with multiple myeloma. It is used in patients whose cancer was already treated with other anticancer therapies. Elotuzumab binds to a protein called CS1, which is found on myeloma cells and some types of immune cells. Elotuzumab may block CS1 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Empliciti and HuLuc63.
Drug (Brand / Generic): EMPLICITI / elotuzumab
Current Indications: multiple myeloma
Marketed by:: Bristol-Myers Squibb Pharma EEIG
Approval Date: 2015
Dosage forms and strengths of EMPLICITI (elotuzumab).
Empliciti 300 mg powder for concentrate for solution for infusion.
Empliciti 400 mg powder for concentrate for solution for infusion.
Find Reference Updates
Alleviare Life Sciences
Alleviare Life Sciences Pvt. Ltd. (India) serves as a facilitator for medical and pharmaceutical products, commencing its operations in 2005. Headquartered in Delhi, India, Alleviare operates nationwide, providing a range of comprehensive services to patients, doctors, hospitals, and government healthcare facilities.
Our specialization lies in facilitating access to medicines, leveraging our expertise in sourcing and providing documentation assistance for programs such as Named Patient Program, Managed Access Program, and Early Access Program. We take pride in ensuring smooth and efficient access to medications for those who require them.
Alleviare India is certified pharmaceutical facilitator / supplier /importer based in india. They are also who GDP certified. One of the pharmaceutical products they offer is “ EMPLICITI (elotuzumab) for injection ”. Confirmation of the order for EMPLICITI (elotuzumab) for injection will be subject to the submission of a valid doctor’s prescription and, if applicable, an import permit.
Get Access to Treatment – EMPLICITI
We have delivered medicines to following cities in India – Ahmedabad, Aizawal, Aurangabad, Barshi, Bengaluru, Bhopal, Cachar, Chennai, Dibrugarh, Hyderabad, Karungapally, Kohima, Kollam, Kolkata, Mumbai, Meghalaya, Mizoram, Sikkim, Nagpur, New Delhi, Pondichery, Pune, Punjab, Thirunananthapuram, Tripura, Wardha.